Latest News
Lilly secures FDA Breakthrough Therapy designation for olomorasib in pancreatic cancer
3 August 2026 - Medicine company Eli Lilly and Company (NYSE: LLY) announced on Monday that it has received U.S. Food and Drug Administration Breakthrough Therapy designation for olomorasib as a monotherapy for adults with previously treated advanced...
Acurx receives FDA guidance supporting ibezapolstat Phase 3 development strategy
3 August 2026 - Biopharmaceutical company Acurx Pharmaceuticals Inc (NASDAQ: ACXP) reported on Monday that it has received further FDA guidance on its ibezapolstat clinical development programme, including the potential for a single Phase 3 trial to ...
Genprex collaborates with Roche Diagnostics on NSCLC biomarker validation
3 August 2026 - Gene therapy company Genprex Inc (NASDAQ: GNPX) disclosed on Monday that it has entered into a collaboration with Roche Diagnostics to validate biomarkers for patient selection in non-small cell lung cancer (NSCLC) clinical trials, su...
Zai Lab's zoci receives FDA orphan designation for neuroendocrine carcinomas
3 August 2026 - Zai Lab Limited (NASDAQ:ZLAB) (HKEX:9688), a research-based, commercial-stage biopharmaceutical company based in China and the United States, announced on Monday that the US Food and Drug Administration (FDA) has granted Orphan Drug D...
Biocon launches Yesafili biosimilar in US ophthalmology market
3 August 2026 - Biopharmaceutical company Biocon Limited (BSE:532523) (NSE:BIOCON) announced on Monday the US commercial launch of Yesafili (aflibercept-jbvf), an FDA-approved interchangeable biosimilar to Eylea 2 mg.The VEGF inhibitor is indicated f...